AssetMark Inc’s Jade Biosciences JBIO Stock Holding History

AssetMark Inc’s Portfolio JBIO Stock Details JBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$22	Hold	1	–	–	﹤0.01%	3532
2026 Q1	$14	Hold	1	–	–	﹤0.01%	3425
2025 Q4	$15	Hold	1	–	–	﹤0.01%	3359
2025 Q3	$9	Hold	1	–	–	﹤0.01%	3174
2025 Q2	$10	Buy	+1	New	+$34	﹤0.01%	2993

Other funds holding JBIO

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Jupiter Topco New York $245B AUM

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AssetMark Inc's JBIO Position: Q2 2026 in Review

AssetMark Inc held its Jade Biosciences (JBIO) position steady in Q2 2026 at 1 share worth $22. The position accounts for ﹤0.01% of the portfolio, ranked #3532.

AssetMark Inc first reported a position in JBIO in Q2 2025 and has held it in 5 quarters since. 153 funds tracked by Wall St. Rank hold JBIO as of Q2 2026.

AssetMark Inc held 1 share of Jade Biosciences worth $22 as of Q2 2026.
AssetMark Inc left its Jade Biosciences share count unchanged in Q2 2026.
Jade Biosciences made up ﹤0.01% of AssetMark Inc's portfolio in Q2 2026, its #3532 holding.
AssetMark Inc first reported a position in Jade Biosciences in Q2 2025 and has held it in 5 quarters since.
153 funds tracked by Wall St. Rank held Jade Biosciences as of Q2 2026.

Based on AssetMark Inc's 13F filing for Q2 2026, filed 30 Jul 2026.